New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

March 2017

Welcome to the March 2017 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the March issue!

The PharmSource Team


PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity

Lead Type February 2017 YTD 2017
Early Development 83 214
Late Development 102 224
Biologic 78 206
Small Molecule 222 499
Parenteral 88 225
Oral 89 188
New Financings 75 144
Total Drug Leads 335 708
Total Device &
Diagnostic Leads
143 281

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


Pipeline Tip

Roche plans to initiate a Phase III trial with gantenerumab for the treatment of Alzheimer’s disease:

  • Therapeutic Area: Alzheimer’s disease/Dementia
  • Dosage Form: Parenteral
  • API: Biologic – Monoclonal antibody

Get deeper information about the likely upcoming needs of Roche, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.

Time to Hit the Road!

by Nathaniel Celentano, Business Development Manager

The pharma trade show season is officially in full swing! Whether your organization is a CRO, CMO, CDMO or any other service provider to the pharma/biotech/device and diagnostics industry, chances are you’ve either recently attended, or will be attending, an industry event over the next few months. If this is the case, make sure you’re taking advantage of the PharmSource Lead Sheet to assist in your meeting planning.

For instance, if you’re heading to the International BIO Convention, make sure you take a look at the 310 biotech/pharma companies located from LA to San Diego in the PharmSource Lead Sheet database. You can use the… read on

Follow the Money to

Bio/Pharmaceutical Opportunities

Spotlight on Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a U.S. public bio/pharmaceutical company that develops potent, small molecule, irreversible aldehyde traps for the treatment of diseases caused by inflammation and inborn errors of metabolism. They raised $10.5 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support R&D activities, including the development of its lead compound, ADX-102, for multiple indications… read on

Follow the Money to

Medical Device & Diagnostic Opportunities

Spotlight on Flow Forward Medical, LLC

Flow Forward Medical is a U.S. private company that develops cardiovascular devices to improve eligibility and reduce maturation failure of arteriovenous fistula vascular access sites for hemodialysis. They raised $1 million in a completion of a Series A venture capital investment.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support the development of its AFE system for arteriovenous fistulas… read on

Bio/Pharmaceutical Outsourcing Report – Special DCAT Edition

Check out the special DCAT Edition of PharmSource’s proprietary industry briefing.

This monthly report reports on and analyzes major developments throughout the CMO industry. It provides expert insight into the significance of industry trends and what they mean for your business.

Deepen your understanding of what’s happening in commercial and clinical dose manufacturing and packaging, API small and large molecule, captive capacity, regulatory developments and more.

Get your copy from the PharmSource team at DCAT. Or click here to download your complimentary copy.

DCAT Week 2017

Pharma Outsourcing: The Numbers, Trends and Partnership Strategies

PharmSource president Jim Miller will provide an in-depth analysis of the market for contract development and manufacturing for drug substances and drug products, including levels of outsourcing, capacity utilization, trends in capital expenditures impacting outsourcing, and strategies for supplier differentiation.

Join us for DCAT’s 2017 Pharma Industry Outlook

PharmSource is also pleased to be the program partner for the 2017 Pharma Industry Outlook session, which will be held Monday, March 20 at 1:15 pm in the Grand Ballroom at the InterContinental Barclay.

PharmSource Lead Sheet

The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

See for yourself how this resource can be a vital tool for building your brand and growing your market share.

To request a test-drive today, contact Nathaniel Celentano at / 1-703-383-4903, ext. 112 (ET USA).